<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="111273"><TitleDisplay>Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance</TitleDisplay><TitleOfficial>Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">PHENOL-C11-12-155</Identifier><Identifier type="NCT">NCT01766570</Identifier></Identifiers><Indications><Indication id="57">Cardiovascular disease</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="153" role="Therapeutic effect marker" type="Biochemical">High-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="215" role="Therapeutic effect marker" type="Genomic;Proteomic">Apolipoprotein B-100</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="284" role="Therapeutic effect marker" type="Genomic">Microphthalmia-associated transcription factor</BiomarkerName><BiomarkerName id="418" role="Therapeutic effect marker" type="Anthropomorphic">Waist circumference</BiomarkerName><BiomarkerName id="425" role="Therapeutic effect marker" type="Proteomic">C-peptide</BiomarkerName><BiomarkerName id="808" role="Therapeutic effect marker" type="Biochemical;Genomic;Proteomic">Insulin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="7411" role="Therapeutic effect marker" type="Biochemical">Oxidized LDL/Albumin ratio</BiomarkerName><BiomarkerName id="9815" role="Therapeutic effect marker" type="Anthropomorphic">Hip circumference</BiomarkerName><BiomarkerName id="11563" role="Therapeutic effect marker" type="Biochemical">Very low density lipoprotein cholesterol</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>polyphenol enriched beverage</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1056385" type="Company"><TargetEntity id="5035550755" type="organizationId">Consortium De Recherche Et Innovations En Bioprocedes Au Quebec</TargetEntity></SourceEntity><SourceEntity id="1079254" type="Company"><TargetEntity id="5038070990" type="organizationId">Institute of Nutraceuticals and Functional Foods</TargetEntity></SourceEntity><SourceEntity id="20602" type="Company"><TargetEntity id="4297631408" type="organizationId">Universite Laval</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"></TargetEntity><TargetEntity id="D002318" type="MeSH"></TargetEntity><TargetEntity id="-1500764314" type="omicsDisease"></TargetEntity><TargetEntity id="182" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20602">Universite Laval</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1056385">Consortium de Recherche et Innovations en Bioprocedes au Quebec</Company><Company id="1079254">Institute of Nutraceutical and Functional Foods</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2012-03-31T00:00:00Z</DateStart><DateEnd type="actual">2015-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-11T08:08:51Z</DateChangeLast><DateAdded>2013-02-22T06:25:36Z</DateAdded><Contacts></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 40 to 65 years&lt;/li&gt;&lt;li&gt;Non-smoking&lt;/li&gt;&lt;li&gt;Overweight (BMI&amp;gt; 27)
&lt;/li&gt;&lt;li&gt;Insulin resistant (fasting insulin&amp;gt; 90 pmol/l, with fasting glycemia &amp;lt; 70  mmol/l and
             &amp;lt; 111 mmol/l after a 120-min oral glucose tolerance test)
&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Diabetes&lt;/li&gt;&lt;li&gt;Chronic diseases&lt;/li&gt;&lt;li&gt;Taking drugs that could affect glucose or lipids metabolism&lt;/li&gt;&lt;li&gt;Major surgery 3 months prior to the study&lt;/li&gt;&lt;li&gt;Weight variation of +/- 10% 6 months prior to the study&lt;/li&gt;&lt;li&gt;Strawberry or cranberry allergy&lt;/li&gt;&lt;li&gt;Consumption of berries rich in polyphenol and/or wine &gt; 3 x per week&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in cardiometabolic statute from baseline to the end of intervention: glucose and insulin concentrations during a 120-min euglycemic-hyperinsulinemic clamp, glucose and insulin concentrations during a 120-min oral glucose tolerance test, insulin sensitivity, c-peptide, hcCRP, IL-6, TNF-alpha and PAI-1 levels, triglycerides, total cholesterol, VLDL-cholesterol, LDL-cholesterol, HDL-cholesterol, apolipoprotein A-1 and B, oxidized-LDL, GDR, MI, beta-cells function</Description><Timeframe>At baseline (at the beginning of the intervention), and at the end of the intervention (6 weeks)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in nutritional variables from baseline to the end of the intervention: food frequency questionnaire</Description><Timeframe>At baseline, and at the end of the intervention period (6 weeks)</Timeframe></Measure><Measure><Description>Change in physical activity habits from baseline to the end of the intervention: physical activity habits questionnaire</Description><Timeframe>At baseline, and at the end of the intervention period (6 weeks)</Timeframe></Measure><Measure><Description>Change in anthropometric measurements from baseline to the end of the intervention: anthropometric measurements (body mass index, waist and hip circumferences)</Description><Timeframe>At baseline, and at the end of the intervention period (6 weeks)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to measure the beneficial effects of an optimized berries
      extracts on diabetes and cardiovascular diseases prevention. The study hypothesis  was that
      including a polyphenol rich berries extract in daily feeding would  improve insulin
      sensitivity, glucose tolerance, pancreatic beta-cells function, lipids and inflammatory profile,
      and oxidative stress markers. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Men and women who would be assigned to a 6 weeks experimental period would consume either the experimental beverage containing polyphenols from berries extracts or a placebo beverage without polyphenols. A 2 weeks stabilization period would precede the 6 weeks experimental period. During these two periods, subjects would be advised to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Institute of Nutraceuticals and Functional Foods (INAF), Laval University</Name><Address1>Quebec</Address1><Address3>G1V 0A6</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Non-insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="168">Subjects at risk of developing disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7734">Obese Class I Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7735">Obese Class II Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7745">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7747">Overweight/obese subjects with insulin resistance</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Insulin resistance</Disease><PatientSegments><PatientSegment><PatientSegment id="11031">Insulin Resistance in Metabolic Diseases Subjects</PatientSegment><SubSegments><SubSegment id="11033">Subjects with obesity</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01766570</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1344"><Endpoint>Assessment of Blood Glucose Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1362"><Endpoint>Assessment of Insulin Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1370"><Endpoint>Assessment of C-peptide Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1389"><Endpoint>Assessment of Beta Cell Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1412"><Endpoint>Assessment of Insulin Sensitivity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1423"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1429">High-sensitivity C-reactive protein (hsCRP)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1433">Interleukin-6 (IL-6)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1441">Oxidized-LDL</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1442">Plasminogen activator inhibitor-1 (PAI-1)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1448">Assessment of tumor necrosis factor alpha (TNFa)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1451"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1452">Assessment of Total Cholesterol</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1453">Triglyceride levels (TG)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1454">HDL-C (High-density lipoprotein cholesterol)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1455">LDL-C (Low-density lipoprotein cholesterol)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1459">VLDL</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1463">Apolipoprotein A-I (Apo A-I)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1465">Assessment of apolipoprotein B (Apo B)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20407"><Endpoint>Assessment of Beta Cell Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20413"><Endpoint>Assessment of Insulin Levels</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20432"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20433">Assessment of blood glucose</SubEndpoint><SubEndpoint disease="Obesity" id="20439">Assessment of glucose tolerance</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20446"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20447">Assessment of apolipoproteins A1</SubEndpoint><SubEndpoint disease="Obesity" id="20449">Assessment of apolipoproteins-B</SubEndpoint><SubEndpoint disease="Obesity" id="20452">Assessment of Triglycerides</SubEndpoint><SubEndpoint disease="Obesity" id="20455">Assessment of LDL-C</SubEndpoint><SubEndpoint disease="Obesity" id="20458">Assessment of cholesterol</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20524"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20528">Assessment of interleukins</SubEndpoint><SubEndpoint disease="Obesity" id="20534">Assessment ofTNF alpha</SubEndpoint><SubEndpoint disease="Obesity" id="20536">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin resistance" id="23272"><Endpoint>Assessment of Insulin Sensitivity</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin resistance" id="23275"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23276">Assessment of blood glucose</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23279">Assessment of insulin secretion</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23280">Assessment of C-peptide</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin resistance" id="23278"><Endpoint>Assessment of Beta Cell Function</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insulin resistance" id="23292"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23293">Assessment of interleukins</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23294">Assessment of plasminogen activator inhibitor-1</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23296">Assessment of TNF</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23299">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Insulin resistance" id="23300"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23303">Assessment of ApoA</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23305">Assessment of apolipoprotein B (Apo B)</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23306">Assessment of HDL</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23307">Assessment of LDL</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23308">Assessment of Total Cholesterol</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23309">Assessment of Triglycerides</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="1501"><Endpoint>Obesity, Body Weight &amp; Fat Tissue Assessment</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1505">Hip circumference</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="6727"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1502">Assessment of BMI</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="1504">Assessment of abdominal circumference</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20653"><Endpoint>Assessment of Physical Examination</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin resistance" id="23313"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23311">Assessment of waist-hip circumference</SubEndpoint><SubEndpoint disease="Insulin resistance" id="23319">Assessment of BMI</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="29701"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="29763">Other patient reported outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin resistance" id="33217"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="33251">Food habit questionnaires</SubEndpoint><SubEndpoint disease="Insulin resistance" id="33261">Other patient reported outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Non-insulin dependent diabetes" id="33857"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="33913">Food frequency questionnaire(FFQ)</SubEndpoint><SubEndpoint disease="Non-insulin dependent diabetes" id="33946">Other patient reported outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="608"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="609">Overweight subjects (Grade 1 obesity, BMI= 25 to 29.9)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Non-insulin dependent diabetes" id="902"><Criterion>Subjects with Insulin Resistance</Criterion></Inclusion><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22429">Obese Class I Subjects</SubCriterion><SubCriterion disease="Obesity" id="22430">Obese Class II Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19730"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19708">Subjects with insulin resistance</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin resistance" id="20198"><Criterion>Insulin Resistance Subjects</Criterion></Inclusion><Inclusion disease="Insulin resistance" id="20225"><Criterion>Subjects with Acceptable Glycemic Levels</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="20227">Acceptable fasting insulin levels</SubCriterion><SubCriterion disease="Insulin resistance" id="20228">Acceptable fasting glucose</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insulin resistance" id="33691"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Insulin resistance" id="20246">Overweight subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="849"><Criterion>Subjects  with Diabetes Mellitus</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="928"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="983"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Obesity" id="15311"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15312">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15342"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15345">Subjects on vitamin/dietary supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="15354"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15365">Hypersensitivity/Contraindication to dietary supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin resistance" id="18010"><Criterion>Subjects  with Diabetes Mellitus</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18043"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18050"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18051"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>23.03 Months</EnrollmentPeriod><EnrollmentRate>2.61 Patients/Month</EnrollmentRate><DateFirstReceived>2012-10-02T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-22T06:25:36Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-02-10T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-08-31T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>